Related Experiment Video
Updated: Jul 16, 2026

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
Published on: September 22, 2017
Optic atrophy after sildenafil use.
Joseph W Sowka1, Maryke N Neiberg, Lori A Vollmer
1Nova Southeastern University, College of Optometry, Ft. Lauderdale, Florida 33328, USA. jsowka@nova.edu
Phosphodiesterase-5 (PDE-5) inhibitors, like sildenafil used for erectile dysfunction, may cause optic neuropathies beyond non-arteritic anterior ischemic optic neuropathy (NAAION). This case suggests a potential link between sildenafil use and other forms of optic nerve damage.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Phosphodiesterase-5 (PDE-5) inhibitors are used for erectile dysfunction and can cause transient visual disturbances.
- Recent reports link these drugs to non-arteritic anterior ischemic optic neuropathy (NAAION).
Purpose of the Study:
- To report a case of optic neuropathy potentially associated with sildenafil use.
- To explore if PDE-5 inhibitors can cause optic neuropathies other than NAAION.
Main Methods:
- A case report of an older male patient with asymptomatic optic neuropathy.
- Neuroimaging and serology were performed to exclude other causes.
- Patient's history of sildenafil use was noted.
Main Results:
- The patient developed an optic neuropathy not typical of NAAION.
- No other underlying cause for the neuropathy was identified.
- The neuropathy appeared to be associated with sildenafil use.
Conclusions:
- Sildenafil use may be associated with optic neuropathies beyond NAAION.
- Further research is needed to establish a definitive causal link.
- Erectile dysfunction medications might be implicated in various optic nerve conditions.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Photoreceptors and Visual Pathways
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy